Emerging applications in mass spectrometry imaging; enablers and roadblocks by Russo, C. et al.
Emerging applications in mass spectrometry imaging; 
enablers and roadblocks
RUSSO, C., HEATON, C., FLINT, L., VOLOACA, Oana, HAYWOOD-SMALL, 
Sarah <http://orcid.org/0000-0002-8374-9783>, CLENCH, Malcolm 
<http://orcid.org/0000-0002-0798-831X>, FRANCESE, Simona 
<http://orcid.org/0000-0002-1381-1262> and COLE, Laura 
<http://orcid.org/0000-0002-2538-6291>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/27669/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
RUSSO, C., HEATON, C., FLINT, L., VOLOACA, Oana, HAYWOOD-SMALL, Sarah, 
CLENCH, Malcolm, FRANCESE, Simona and COLE, Laura (2020). Emerging 
applications in mass spectrometry imaging; enablers and roadblocks. Journal of 
Spectral Imaging, 9, 1-21. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Correspondence
L.M. Cole (L.Cole@shu.ac.uk)
Received: 31 July 2020
Revised: 13 October 2020
Accepted: 14 October 2020
Publication: XX October 2020
doi: 10.1255/jsi.2020.a13
ISSN: 2040-4565 
Citation
C. Russo, C. Heaton, L. Flint, O. Voloaca, S. Haywood-Small, M.R. 
Clench, S. Francese and L.M. Cole, “Emerging applications in mass spec-
trometry imaging; enablers and roadblocks”, J. Spectral Imaging 9, a13 
(2020). https://doi.org/10.1255/jsi.2020.a13
© 2020 The Authors
This licence permits you to use, share, copy and redistribute the paper in 
any medium or any format provided that a full citation to the original 
 paper in this journal is given.
1C. Russo et al., J. Spectral Imaging 9, a13 (2020)
volume 1 /  2010
ISSN  2040-4565
In thIs Issue:
spectral preprocessing to compensate for packaging film    /    using neural nets to invert 
the PROSAIL canopy model
JOURNAL OF
SPECTRAL
IMAGING
JsI
Peer Reviewed Review openaccess
Emerging applications in mass spectrometry 
imaging; enablers and roadblocks
Cristina Russo,a Cameron Heaton,b Lucy Flint,b Oana Voloaca,b Sarah Haywood-Small,b Malcolm Ronald Clench,b 
Simona Franceseb and Laura Margaret Coleb,*
aMiddlesex University, The Burroughs, Hendon, London NW4 4BT, UK
bSheffield Hallam University, Howard St, Sheffield, S1 1WB, UK
Contacts
Cristina Russo: https://orcid.org/0000-0002-9776-8897
Cameron Heaton: https://orcid.org/0000-0002-4479-3861
Lucy Flint: https://orcid.org/0000-0001-6187-3081
Oana Voloaca: https://orcid.org/0000-0003-0131-6907
Sarah Haywood-Small: https://orcid.org/0000-0002-8374-9783
Malcolm R. Clench: https://orcid.org/0000-0002-0798-831X
Simona Francese: https://orcid.org/0000-0002-1381-1262
Laura M. Cole: L.Cole@shu.ac.uk, 
https://orcid.org/0000-0002-2538-6291
Mass spectrometry imaging (MSI) is a powerful and versatile technique able to investigate the spatial distribution of multiple non-labelled endog-
enous and exogenous analytes simultaneously, within a wide range of samples. Over the last two decades, MSI has found widespread application 
for an extensive range of disciplines including pre-clinical drug discovery, clinical applications and human identification for forensic purposes. 
Technical advances in both instrumentation and software capabilities have led to a continual increase in the interest in MSI; however, there are still 
some limitations. In this review, we discuss the emerging applications in MSI that significantly impact three key areas of mass spectrometry (MS) 
research—clinical, pre-clinical and forensics—and roadblocks to the expansion of use of MSI in these areas.
Keywords: mass spectrometry imaging (MALDI), secondary ionisation mass spectrometry (SIMS), desorption electrospray ionisation (DESI), laser 
ablation inductively coupled plasma (LA-ICP), liquid extraction surface analysis (LESA), imaging mass cytometry (IMC), biomolecular imaging, 
technical advancements, imaging software
Introduction
Observing the spatial distribution of an endogenous or 
exogenous molecule has great potential for many appli-
cations. Mass spectrometry imaging (MSI) has evolved 
from existing MS techniques enabling identification and 
quantification of an analyte, whilst retaining spatial infor-
mation. In MSI, spectra are acquired in regular rows or 
raster lines to cover a region of interest (ROI) on a sample. 
The mass spectrum plotting mass to charge ratio (m/z) 
values versus ion intensities is generated for each raster 
point or pixel. These can then be reconstituted, using 
software, into a molecular “image” where the distribu-
tion of individual or multiple m/z values can be selected 
and visualised within the sample. MSI, therefore, enables 
the simultaneous study of the distribution of multiple 
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molecular species in a sample in an untargeted, label-free 
manner.
Since its development for biomolecular imaging by the 
Caprioli group in 1997,1 MSI has established itself to 
encapsulate many bioanalytical applications, analysing 
a variety of samples including single-cells, three-dimen-
sional cultures, animal tissues, whole rodents, patient 
microarrays and biopsies, fingermarks, and human hair.2–8 
Over the last decade, technical advancements in instru-
mentation have allowed vast improvements in MSI speed, 
spatial resolution and sensitivity. In addition, MSI modali-
ties employing a wide range of ionisation sources have 
been developed including:
	 matrix-assisted laser desorption ionisation (MALDI), a 
soft ionisation technique which employs laser energy 
and an absorbing matrix;
	 secondary ionisation mass spectrometry (SIMS), using 
a focused primary beam of ions resulting in the analysis 
of secondary ions ejected from the sample surface;
	 desorption electrospray ionisation (DESI), an ambient 
ionisation methodology via a solvent spray;
	 laser ablation inductively coupled plasma (LA-ICP) 
involves a nanosecond-pulsed laser to the sample 
surface; and
	 liquid extraction surface analysis (LESA) via direct 
micro-junction solvent extraction.
Early images took 1–2 min per pixel at 25 µm spatial 
resolution,1 compared to modern-day instrumentation 
where the image acquisition time has decreased by a 
factor of up to 20 times.9 This is an astounding advance-
ment in two decades and has allowed ever more diverse 
applications to be undertaken; for example, MALDI-MSI 
of a whole rodent body section at 100 µm pixel size 
has been reported as being acquired in less than 13 h 
(Figure 1).
MSI has had a dramatic influence on the pharmaceu-
tical industry, particularly in pre-clinical drug discovery. 
The development of high-resolution imaging has enabled 
precise localisation of therapeutics simultaneously with 
tissue biomarkers for effective compound efficacy and 
safety profiling. MSI can be used to identify failures in 
drug development thus preventing high attrition rates, 
significantly reducing financial costs and project timings.
Improvements in spatial resolution, acquisition time and 
reproducibility have meant that the use of MSI in clinical 
settings seems closer than ever. The idea of carrying 
out MS-based analysis either in situ or during real-time 
surgery on patient biopsies will contribute to making 
Figure 1. A comparison of imaging capabilities in terms of spatial resolution, area 
of acquisition and speed over the last two decades. a) Shows a MALDI image of an 
aggregate of human buccal mucosa cells at 25 µm laser spot size in 1997. b) In con-
trast, a MALDI image of an entire rodent body section at 100 µm in 2017 (not to 
scale, adapted from Reference 1 and Chemical & Engineering Magazine, front cover, 
5 June 2017 [credit ImaBiotech]).
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precision medicine a reality.10 Precision medicine is the 
ideal process in diagnosis, care and treatment of one’s 
condition, a step away from the classic “signs-and-symp-
toms” approach. Monitoring the alterations of specific 
endogenous molecules (such as lipids, peptides and 
metabolites) in a spatially-resolved manner can provide 
valuable insights into the normal or diseased state and 
can be used as a personalised tool for diagnosis, prog-
nosis and monitoring of disease. Already, MSI in clinical 
research has led to the discovery of disease biomarkers, 
especially in oncology, and helped understanding the 
molecular mechanisms causing certain pathologies.11,12 
An insightful study by the Prideaux research group in 
2018 reported on mycobacterial biomarkers and the 
co-registration of drugs to treat tuberculosis in animal 
models using MALDI-MSI.13 Images included the spatial 
distribution of bacterial populations in distinct regions 
of ex vivo tissues with the ability to visualise patterns of 
drug delivery.
MSI remains a largely academic exercise in the field 
of forensic analysis apart from its use in the analysis 
of fingermarks. Both SIMS and MALDI feature in the 
Home Office Fingermark Visualisation Manual (FVM)14 
as Category C techniques indicating processes “at a 
developmental stage exhibiting potential [...] an optional 
process for occasional operational use […] when Category 
A processes have been exhausted”. Category A processes 
are well established and include optical (i.e. multispectral 
imaging, infrared reflection, ultraviolet reflection etc.), 
chemical (i.e. superglue fuming, ninhydrin, acid dyes etc.) 
and physical processes (i.e. vacuum metal deposition, 
enhancing powders etc.).
Unlike SIMS, due to the vast body of knowledge, wider 
compatibility with Category A processes and implementa-
tion in some casework, MALDI-MSI is now in the process 
to be promoted, in the next FVM edition, to Category B 
indicating an “established process [...] likely to offer benefits 
[...] for occasional operational use [...] and when all Categories 
A options have been exhausted”. Additionally, amongst all 
the MSI techniques, to the best of the authors’ knowl-
edge, MALDI has been the only one that has been used 
in operational casework both in the UK15 and overseas. 
These circumstances are testimony to the continuous 
advancements of MALDI-MSI in this field. However, full 
implementation (including in a court of law) is still some-
what hindered by the challenge of undertaking method 
validation which would require testing robustness and 
effectiveness of the methods against a large number of 
fingermarks from a large number of donors, surfaces of 
depositions, environmental conditions and against an 
as large number of forensic enhancement techniques as 
possible. This is not considered original work by funders 
and it is often the given reason why such studies are 
not funded, despite being the last hurdle prior to full 
operational implementation. This potentially negates 
the considerable impact on the criminal justice system 
and on safe societies that operational implementation of 
MALDI-MSI could offer.
The aim of this perspective is to look at the issues in 
MSI, both technical and non-technical, that are currently 
“roadblocks” to its further adoption in real-world appli-
cations. The roadblocks to be discussed are: obtaining 
appropriate samples, complex sample preparation, long 
sample analysis times, poor molecular specificity, poor 
sensitivity and poorly developed data processing tools. 
The literature has been examined and proposed solutions 
that have emerged in recent years for these particular 
roadblocks are discussed.
Roadblocks and enablers
Obtaining samples
Clinical samples
Many clinical institutions support research by providing 
tissue samples harvested from patients. Public opinion 
has tremendously changed with more and more people 
being willing to donate biological material in order to 
support further research. However, such samples are a 
finite resource and, therefore, experimentation with them 
must be justified ethically. In addition, many MS laborato-
ries have little experience in the safe and ethical handling 
(and storage) of healthy and diseased human tissue.
There are three main strategies in place for obtaining 
clinical samples for MSI studies: use of a tissue bank 
(banking model), a prospective collection model and a 
combination of the two.16 The prospective collection 
model allows a pre-selective element where the desir-
able tissue type is stated, type of storage and corre-
sponding number of samples required before collection. 
Whereas acquiring samples via a banking model limits 
the choice and relies on what is already archived. In addi-
tion to these methods there is also “catch as catch can”, 
which describes another, yet unreliable tissue collection 
strategy which potentially risks legal and ethical viola-
tion. This is so, due to there being no quality controls or 
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quality assurance in place to ensure that suitable storage 
and tissue processing meets national standard operating 
procedures. Samples are taken as and when tissue is 
available on an ad hoc basis, reliant on when collection 
timescales allow. “Catch as can” methods can, therefore, 
result in tissue of substandard grade and not being a true 
representation of the tissue from its origin.
Pre-clinical samples
Animal tissues are conventionally used for pre-clinical 
studies in drug disposition, efficacy, safety and model 
characterisation, this due to the in vivo conditions closely 
resembling human metabolic processes. Such tissues are 
readily available with pharma, contract research organi-
sations and universities having licensed facilities for the 
ethical use of animals in scientific research. Animal tissues 
have been widely used in MSI for the study of disease 
and drug absorption/efficacy/toxicity.1,4,5 Whilst the 
use of animal models in pre-clinical studies is currently 
the accepted paradigm, there are issues on the horizon. 
Attitudes in society to the use of animals in research are 
changing, and criticisms that animals are an inappropriate 
model to represent the human body are becoming more 
widespread.17 Tissue engineered models are emerging as 
a valuable complementary/alternative in vitro tool to the 
use of animals in pre-clinical drug discovery and have the 
potential to make significant positive impact on the 3Rs—
reduction, replacement and refinement—agenda for the 
use of animals in scientific research.18 The combination 
of 3D tissue culture systems with MSI, offering, as it does, 
the ability to study drug and drug responses simultane-
ously in a rapid label-free manner, is a research field that 
has huge promise for the future.
The Hummon group reported the use of tumour 
spheroids with MSI and they were able to demonstrate 
the ability of the technique to identify specific hypoxic 
regions within colon cancer spheroids.3 MSI in combi-
nation with spheroids has been used for the detection 
of chemotherapeutics, their metabolites and biological 
responses within.19–21 Liu et al.21 described drug distri-
butional patterns of irinotecan within the necrotic core of 
spheroids 24 h after treatment, stating high metabolism 
within the outer regions due to the presence of irino-
tecan metabolites.
Organoid models, particularly 3D models of full thick-
ness skin, have been extensively used in MSI.22,23 This 
combination has been used to evaluate drug penetration 
and drug effects, wound healing and infection.24,25 In 
a recent report22 a validated quantitative methodology 
employing a 3D skin model was used to study the effect 
of an enhancer for drug absorption within the epidermis 
of a living skin equivalent model24 (Figure 2). Successful 
demonstration of these capabilities has proved high 
value for pre-clinical drug development specifically for 
compound efficacy and safety analysis. Yet, this area of 
research is still emerging, so the extent of applications 
in MSI with 3D cultures holds great potential. This is 
specifically due to recent developments in tissue engi-
neering that have produced microfluidic devices and 3D 
bioprinting technology with more representative micro-
environment conditions of in vivo.
Samples for forensic analyses
Fingermark imaging is one of the widest reported appli-
cations of MSI in forensics. The recovery of intelligence 
around a suspect or the crime being investigated from 
the molecular content of a fingermark (profiling), whilst 
visualising the interested molecule on the fingermark 
ridge pattern (imaging) (Figure 3), offers unprecedented 
information to the investigators.26,27
This information can be used to triage the fingermarks 
within the crime scene management strategy and/or to 
narrow down the pool of suspects. However, one of the 
most used forensic protocols for collecting fingermarks 
at the crime scene includes enhancement of the marks 
using powders applied from the same pot with the same 
brush. This inevitably introduces cross-contamination 
of evidence which, though not affecting the biometric 
information, affects the forensic meaning of a given 
substance detected in a fingermark. In addition, several 
Police Forces in the UK are moving away from physical 
fingermark recovery (for example through tape lifting) and 
towards electronic photo capture and real-time remote 
transmission. Should this process be extended to major 
crimes as well, where MALDI-MSI finds application, the 
opportunity to offer intelligence, complementary to that 
yielded by classic police investigation, will be lost. If the 
availability and the “molecular meaningfulness” of finger-
marks are to be maintained, both of these roadblocks 
must be considered at the point of sample recovery. One 
way around sample cross-contamination was reported by 
Reed et al.28 with the development of a gun depositing 
the powder in a contactless manner. The device was 
described in the UK patent application GB 2504276, 
which was let to lapse as it is under further industrial 
development. Of course, the only way to avoid exclusive 
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Figure 2. A) MALDI-MSI of a living skin equivalent model, Labskin, 
showing marker ions of the stratum corneum (in green, [M + H]+; m/z 
264) and the epidermis (in red, [M + H]+; m/z 184). B) Histological 
staining of the same section after MSI analysis (adapted from Pro-
teomics, front cover, 18 July 2018 [credit C. Russo]).
Figure 3. MALDI-MSI of condom-contaminated fingermarks. The 
figure illustrates the MALDI-MS images of 32-mer, 33-mer and 
34-mer PEG ion signals as well as a small sample of the many fatty 
acids detected, from a lifted fingermark previously visualised by 
irradiation with a laser at a wavelength of 532 nm using an orange 
viewing filter (549 nm) and photographed using a Nikon D300 
camera. The complete ridge pattern is provided by the image of 
the total ion current (TIC). The fingertip was previously contami-
nated by touching a Condomi max Love condom. (Reproduced and 
adapted by permission of The Royal Society of Chemistry from 
Reference 27).
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mobile transmission of the evidence and to influence 
practice would be to provide continuous examples in 
actual police casework that the intelligence provided by 
the application of MSI is additional and complementary 
to police investigation, as demonstrated by Bradshaw 
et al.27 Presently, in major crimes (murder, rapes etc.) 
fingermarks are still being lifted.
Sample preparation
Pre-preparation
Embedding and sectioning
Maintaining tissue integrity is imperative in MSI experi-
ments in order to preserve analyte localisation. Commonly, 
analysis is conducted on cryo-sectioned tissue sections, 
often collected and prepared with MSI as a primary 
analytical endpoint. Smaller, more fragile tissues often 
require supportive materials, embedding samples for 
handling purposes. Embedding several tissues from the 
same study has also proven beneficial for reducing sample 
preparation time and preventing molecular changes via 
“freezer burn” to tissue sections in the cryostat.29 MSI 
compatible materials that do not interfere with analysis 
include gelatin30 and carboxymethylcellulose (CMC).31 
Alternatively, poly[N-(2- hydroxypropyl)methacrylamide] 
(pHPMA) was specifically developed for MSI, as it is liquid 
at –8 °C.32 This low temperature minimises possible 
thawing of tissues unlike gelatin which requires higher 
temperatures (~25–50 °C) during embedding. A more 
recent study optimised a sample embedding protocol 
with an ice-cold hydrogel composed of hydroxypropyl 
methylcellulose (HPMC) and polyvinylpyrrolidone 
(PVP).33 Dannhorn et al.33 assessed the compatibility of 
the hydrogel demonstrating no interfering effects with 
MALDI, DESI and SIMS imaging methods or delocalisa-
tion of analytes.
In a clinical setting, the standard preservation process 
for tissues collected for pathology is to formalin fix 
and then paraffin embed the tissue to create so called 
Formalin Fixed Paraffin Embedded (FFPE) tissues. Such 
samples are suitable for indefinite storage. Despite the 
advantages of the use of fresh frozen tissue, in terms of 
the range of molecules that can be detected within, for 
widespread adoption of MSI in the clinic to occur, ways 
of preparing FFPE tissues are required. Various ways 
to achieve this have been developed including adding 
a de-paraffinisation step prior to matrix application,34 
addition of enzymes or changing digestion strategies.35 
Moreover, section thickness has been reported to influ-
ence peak intensity, with 1 µm sections presenting up to 
three-fold higher intensities compared to conventional 
5 µm sections.36,37
Storage
Appropriate storage for tissues is crucial to retain sample 
integrity and ensure accurate results. When consid-
ering conventional immunohistochemistry, whole tissue 
samples can be stored at –80 °C up to a year without 
degradation that would impact on the study of protein 
distribution. Storage of tissues and sectioned samples 
for MSI presents more challenges as tissue sections 
are vulnerable to excessive ice formation and conden-
sation, resulting in molecular degradation and delo-
calisation. Efforts to reduce this impact have included 
steps to remove excess moisture by drying the sample 
either by desiccation or freeze-dry techniques.38,39 This, 
however, can add to sample preparation time (~2 h) 
and is not completely effective. Alternatively, a recent 
study conducted by Swales et al.40 established a protocol 
of desiccating the sample with nitrogen after thaw 
mounting, and then vacuum packing the slides prior to 
storage. Maintaining the sample in a vacuum environ-
ment ensures that the molecular distribution within a 
tissue is stored in its “life-like” state. By employing this 
technique, the study observed significant stabilisation of 
molecules and minimised delocalisation, thus improving 
imaging results.
Sample preparation issues associated with 
specific imaging modalities
MALDI
Matrix application is critical to success in preparing 
samples for MALDI imaging. Selecting an appropriate 
matrix is critical, as is the application. There are four 
well-established methods of applying matrix to samples 
before MSI; automatic and manual spray systems, subli-
mation and acoustic vibrational spotters. Spray coating is 
the most popular method of application, with a variety of 
commercial spray systems on the market (i.e. SunChrom 
SunCollect and HTX TM-Sprayer).41,42 The number of 
layers, flow rate and speed of deposition can all be 
accurately controlled. The main advantage of automatic 
sprayers are that ROIs can accurately be selected, leaving 
unwanted areas free of matrix and making efficient use 
of matrix. However, they are slower than other methods. 
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Manual sprayers cover the whole sample and the quantity 
of matrix applied is less precise, but are a much simpler 
and cheaper alternative. Sublimation results in a homog-
enous matrix coating with a very small crystal sizes, and, 
importantly, without the use of solvents that can cause 
analyte delocalisation in certain samples. Acoustic spot-
ters (such as Labcyte Portrait 630 and Bruker ImagePrep) 
can apply very small droplet sizes and have their param-
eters easily changed, but are slow and expensive.43,44
Generally, the presence of solvents, when matrix 
sprayers are employed, results in the formation of rela-
tively large crystals in diameter (30–60 µm), larger than 
the smallest laser spot size for most MALDI instruments 
(5–15 µm). Advances in the complexity of commercial 
sprayers allow the user to control the sample stage 
temperature, enabling further refinement of the speed of 
crystal formation, consequently allowing a reduction in 
crystal size. Acoustic vibration spotters produce droplet 
sizes in the region of 20–50 µm, whereas sublimation 
can generate <1 µm crystals. Allowing fine-tuning of 
matrix application parameters can lead to homogenous 
deposition and smaller, more consistent crystal formation, 
which can translate into higher resolution molecular 
imaging.
Ambient techniques
Ambient techniques benefit from virtually no (or very 
little) sample preparation steps, and this has been a major 
contribution to their recently gained popularity. It enables 
swift analysis upon receipt of the sample, drastically 
improving throughput times. One example of the useful-
ness of this comes from work on drug-induced lipidosis in 
rodent tissues reported by Dexter et al.4 They used DESI 
imaging to study the distribution of amiodarone, a well-
known lipidosis-inducing drug. It was shown that not only 
does DESI provide operational simplicity at atmospheric 
pressure and requires no sample preparation, but it also 
allows for repeat analysis of the same section several 
times. This drastically reduces delocalisation, allows for 
application of simple registration routines for data acqui-
sition, and allows for detection of molecules in both posi-
tive- and negative-ion mode without the need for serial 
sectioning. However, a limitation of this technique still 
lies in the relatively poor spatial resolution (30–150 µm) 
when compared to other established imaging platforms.4
The ultimate goal of carrying out MSI in vivo with no 
sample preparation needed is becoming more and more 
feasible. Whilst there appear to be no reports of real-time 
MSI in surgical settings to date, tools such as the iKnife 
and MasSpec Pen have been shown to identify border-
line tumours in real-time by analysing specific biomarkers 
with no sample preparation required.45,46 These tech-
niques do have the potential to be coupled with MSI 
and provide qualitative and spatial information about the 
tumour microenvironment to aid a surgeon to distinguish 
the cancerous tissues in “real-time” in a manner that has 
never been envisioned before.
Sample preparation issues associated with 
specific analyte/sample types of current 
interest
Hair
Although fingerprints make up most publications in 
forensic MSI, other forensically relevant evidence have 
had this technique applied. Strands of hair (in the order 
of 20–100 mg for example) are normally the specimen 
of choice for determining chronic drug use.47 To give an 
estimated window of time exposure, the hair shaft can 
be cut into 1 cm lengths and analysed typically by liquid 
chromatography-MS or gas chromatography-MS.48,49 
However, following the growing interest in forensic MSI, 
hair has been molecularly imaged to give a visual indica-
tion of drug abuse. This method reduces sample prepara-
tion time, allows the detection of a narrower time frame 
and also reduces the amount of sample required. Beasley 
et al.50 detected notoriously poorly ionising cannabinoids 
in single hair stands for the first time using a combination 
of cannabinoid derivatisation and MALDI-MSI. External 
contamination is a present challenge for hair analysis and 
external solvent washes are required in order to remove 
such contaminants.
To facilitate another dimension of hair analysis, Flinders 
et al.51 developed a novel device which allowed preci-
sion, longitudinal sectioning of hair strands enabling clear 
lateral visualisation of the cuticle, medullar and cortex. 
This group, from the Netherlands, then also success-
fully demonstrated an approach using multiple-reaction 
monitoring (MRM) to detect metabolites in hair sections 
differentiating between cocaine users and externally 
contaminated hair.8 This is a benefit unique to MSI, which 
can simultaneously perform MRM and provide the visual 
distribution of the exact location of these analytes (Figure 
4). Analysis of the hair samples took around 3 h compared 
to the current methodology which takes 1 h; however, 
sample preparation for the current methodology takes 
around 1 day, whilst MALDI-MS sample preparation is 
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1 h, thus indicating a significantly higher overall speed of 
hair processing using MALDI-MSI.
Biopharmaceuticals
Biopharmaceuticals have received considerable attention 
over recent years, becoming one of the fastest growing 
sectors within the pharmaceutical industry. The rapid 
growth of biopharmaceuticals has thus challenged MSI 
to progress their detection and imaging with the same 
momentum. Detecting large molecular mass molecules 
of ~40–150 kDa by MSI presents issues associated with 
their low ionisation efficiencies leading to poor sensitivity, 
which have hindered the detection of biologics within 
tissues.
The employment of proteomic strategies for the 
detection of biologics in vivo has had some success. An 
in-source decay (ISD) top-down fragmentation approach 
exploited by Ait-Belkacem et al.52 detected the mono-
clonal therapeutics, bevacizumab and palivizumab within 
the brain. With the ability to rapidly fragment proteins, 
the ISD approach has no limitation on mass range proving 
beneficial for larger molecular weight imaging. Yet this 
strategy has its drawbacks. With the lack of precursor 
ion selection, due to in-source fragmentation, identifying 
biologic-specific peaks in complicated spectra amongst 
multiple proteins proves challenging, especially since 
this technique produces relatively low ion yield of frag-
ments. However, the ISD approach does allow for second 
Figure 4. MALDI-MS/MS image of longitudinally sectioned drug users’ hair 
samples (insert shows optical image of longitudinally sectioned hair). The 
MALDI-MS/MS image shows the differential distribution (quantities and 
location) of the product ion at m/z 182, derived from the precursor ion of 
cocaine at m/z 304 within the hair shaft of two cocaine users. The length of 
the analysed hair samples was 4 cm corresponding to a hair growth period 
of 4 month. Since the spatial resolution along the hair is 150 μm, each pixel 
is equivalent to approximately 12 h of growth (adapted and reproduced from 
Reference 8 under the Creative Commons Licence http://creativecommons.
org/licenses/by/4.0/).
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fragmentation known as T3-sequencing, which will enable 
amino acid sequencing for confident identification.53
Alternatively, a novel approach of an on-tissue reduc-
tion and alkylation was demonstrated by Liu et al.54 for 
the detection of a monoclonal drug, cetuximab in tumour 
spheroids and organoids. The method separates the anti-
body into heavy and light chains for the detection at 
a smaller mass range, i.e. from 150 kDa to 20–50 kDa. 
Limitations of this practice can result in low fragmenta-
tion efficiencies, which can impact the ability to accu-
rately isolate the ion of interest from considerable signal 
of endogenous species. Initial profiling of the reduced 
antibody is, therefore, necessary to correctly identify the 
biologic. A significant lack of publications demonstrates 
the need for further method development for biologic 
imaging. Yet with the progress of the two reports stated 
there is potential for MSI in pre-clinical drug develop-
ment to be utilised in the biopharmaceutical industry.
Sample analysis
Time of acquisition
One of the main roadblocks discussed which prevents 
MSI progressing into routine use in industry is the time 
taken for image acquisition. The overall time required 
for an MSI experiment to be undertaken encompasses 
sample preparation, acquisition time and data processing. 
Hence, much of the progress in technological develop-
ment has focused on shortening the time it takes to cover 
these stages.
In MALDI imaging, the spot-to-spot acquisition time 
and the laser repetition rate have historically been 
limiting factors in the overall speed of acquisition. The 
widespread adoption of raster imaging (line scanning) 
for MALDI-MSI and in addition to the increase in the 
typical repetition rate of lasers used to 1–2 kHz, repre-
sent real game changers in the speed of acquisition for 
this modality. Typically, an area of the size of a fingermark 
may have taken more than 20 h to be imaged with a 
relatively good spatial resolution (100 μm pixel size) even 
on an instrument fitted with a 1 kHz laser, if acquiring in 
spot-to-spot mode. In line scanning mode this can be 
achieved in 30 min. Recent advances have pushed the 
speed boundaries even further by the integration of the 
µMALDI source on instruments such as Waters QTOF 
Synapt (Waters, Wilmslow, UK) and the Bruker Rapiflex 
(Bruker, Bremen Germany).55 Now an image, the size of 
a fingermark (at 100 μm pixel size), can be acquired in as 
little as 10  min. Such a significant increase in the speed of 
acquisition has benefits for all fields using MSI.
Spatial resolution
Another area that has seen constant improvement in 
MSI is the spatial resolution achievable. In less than 10 
years, the available spatial resolution has improved on 
commercially available instrumentation from 100 μm 
down to sub-micron. The Spengler group published a 
study pertinent to this field, looking at the correlation 
between the formation of ions and laser spot size in high-
resolution MALDI imaging.56 In addition, they reported 
on laser optical resolution and the dependence of ion 
signal intensities on both laser fluence and laser beam 
profile within the spatial resolution range 1.1–8.4 µm. 
The authors indicated that their data supported the view 
that there were no changes to the desorption/ionisation 
model when smaller laser spot sizes are employed. They 
contrasted this with earlier work that suggested that 
thermal processes dominated at smaller spot sizes.57 
There are many fields where improved spatial resolution 
in images offers opportunities to explore new science. In 
the field of fingermark analysis, high spatial resolution 
is particularly important to provide as many minutiae as 
possible (local characteristics of the fingermark ridge 
pattern, unique, as a whole, to an individual) helping with 
the identification of a suspect. The increased lateral reso-
lution to ~15 µm with the µMALDI source enables the 
provision of comprehensive biometric information, as well 
as accurately localising forensically relevant compounds. 
For example, a species that is localising precisely on the 
pores of the ridges would indicate a substance that has 
genuinely originated from the owner of the mark and 
this information is very helpful to formulate activity level 
proposition at an investigative and judicial debate level.
Quantitation
Quantitative (Q)-MSI has emerged as a “hot” topic within 
pharmaceutical development. Simultaneous quantifica-
tion and localisation of a targeted drug and its active 
compounds has been demonstrated by MALDI, DESI, 
LESA and LA-ICP-MS.58–62 Establishing MSI for abso-
lute quantitation, however, has presented challenges in 
obtaining high precision, accuracy and reproducibility. 
Due to the well-documented issues with ion suppres-
sion analyte extraction and matrix effects, the funda-
mental aspects of MSI need to be considered in order to 
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produce fully validated MSI methodology for quantitative 
analysis.63–65
In Q-MSI, a calibration curve is necessary for the analyte 
of interest (AOI). Choosing a method to include standards 
into the experiment in order to construct calibration 
curves is dependent on the nature of the study, i.e. the 
tissue type or imaging technique. Spotting standard solu-
tions directly onto the target plate has been discarded for 
most imaging techniques due to the failure to replicate 
tissue matrix effects.66 As an alternative spotting stan-
dards onto or under a control tissue or similar matrix, 
i.e. gelatin, is often used to recreate ion suppression 
conditions.67,68 A criticism of this approach, however, is 
the calibration variability influenced by a tissue’s hetero-
geneous environment. Russo et al.24 reported, however, 
precise use of the spotting technique by applying nano-
litre volumes of a standard solely within the epidermis of 
a 3D skin model to replicate the absorption distribution 
region of the drug of interest.
Spiked tissue homogenates are commonly used to 
create matrix matched standards for accurate replication 
from sample to sample.58,62 Preparation of these mimetic 
tissue models generally requires large volumes, which can 
be costly and time consuming. Recently, a study devel-
oped a method of freezing serial spiked tissue homog-
enates within a mould to create a calibration “scale bar” 
against a sample.69 This method increases the efficiency 
of the experiment and reduces preparation time. The 
amount and cost of control tissues for homogenisation 
is still a drawback, however, and the process is labour 
intensive when compared to spotting techniques.
To increase the potential of Q-MSI analysis, an internal 
standard (IS) can be added to normalise differences 
in ionisation response across a tissue. An IS must be 
chemically similar to the target analyte and is ideally a 
deuterated compound. In the literature there are multiple 
techniques reported for introducing an IS into MSI 
experiments. For example, applying the IS beneath the 
tissue has been reported for MALDI analysis as matrix 
can extract both the AOI and IS from the tissue during 
crystallisation. Alternatively, in MALDI-MSI the IS can be 
premixed with the matrix. More frequently, application of 
IS by spraying or by use of the spotting techniques are 
used for other imaging modalities due to the efficiency 
of IS extraction.59,69,70 There is disagreement, however, 
whether this accurately reflects the analyte extraction 
from the tissue. However, by spraying or spotting an IS it 
enables the study of whole tissue sections or a ROI.
The use of Q-MSI has not been widely reported for 
clinical applications, even though the ability to monitor 
and quantify drug penetration in tissues is a clear medical 
need. The heterogeneity of patient tissues is an obvious 
roadblock on conventional Q-MSI methods. Sammour et 
al.71 have recently published a proof-of-concept study 
on the integration of Q-MSI into a clinical application. A 
dilution series was generated by spotting calibrants onto 
porcine tissue adjacent to tumorous and non-tumorous 
patient tissues treated with imatinib. Additionally, an IS 
of deuterated imatinib was sprayed across all tissues. 
The novel aspect was the employment of a non-linear 
regression curve as a superior calibration method based 
on imatinib-containing pixels (S/N ≥ 3). This was used 
to create an accurate and precise methodology that 
was able to handle highly heterogeneous tissues with 
different amounts of AOI. Whilst the methodology was 
not fully validated, this study demonstrates a great appli-
cation of Q-MSI into clinical pharmacological studies and 
thus is a major step forward for quantitative capabilities.
Other technological enablers
Imaging mass cytometry
Efforts to increase spatial resolution for sub-cellular detail 
in tissues have seen the development of a novel, high-
resolution imaging technique, imaging mass cytometry 
(IMC), otherwise known as CyTOF imaging. The adapta-
tion of high parameter flow cytometry combined with 
laser ablation and time-of-flight (TOF) MS fundamen-
tals provides capabilities to analyse 50 specific markers 
simultaneously within a single tissue sample.72,73 Before 
laser ablation, sectioned tissue undergoes immuno-
staining with metal-labelled antibodies; the signal is then 
amplified with a metal chelating polymer or nanoparticle. 
CyTOF is a powerful multiplex imaging platform that can 
analyse frozen and FFPE tissue samples at a spatial reso-
lution between 1 µm and 500 nm, with capabilities for 
quantitative analysis.74 IMC can reveal molecular signa-
tures with intricate detail in tissues applied to a range of 
studies from animal tissues in pre-clinical drug develop-
ment, to patient cohorts or archived samples in clinical 
applications. An informative review on the principles 
and emerging applications of IMC has been published 
by Chang et al.,75,76 which included their own images 
as a result of collaboration with the Hedley group and 
the Fluidigm® team in Canada (Figure 5). IMC was first 
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commercialised in 2014 by Fluidigm®, and validated by 
the Bodenmiller group, identifying tumour microenvi-
ronment heterogeneity in FFPE human breast cancer 
samples.77 Since this report, IMC has been established 
for single-cellular phenotyping in a range of clinical 
cancerous and diseased tissues,76–79 in addition to identi-
fying biodistributions of cisplatin in healthy and tumorous 
tissues.80
Although IMC is a powerful platform, there are ongoing 
developments to further improve its capabilities across 
applications. A limited number of researchers have access 
to the Hyperion IMC instrumentation due to relatively 
expensive running costs and approximately £1.2 million 
to purchase. Therefore, projects employing IMC have to 
consider the project costs. Additionally, the acquisition 
time alone takes 2 h per 1 mm2, with time to prepare 
slides for analysis requiring 2 days. Yet, the standard 
quality of data produced by IMC provides exceptional 
detail that has significantly improved how researchers 
analyse tissues, thus expanding possibilities of many 
biological applications and emerging as a critical tool for 
research development and clinical outcome.
In addition to IMC, the development of a similar 
instrumentation, multiplexed ion beam imaging (MIBI) 
commercialised by IONpath® is a direct competitor for 
sub-cellular imaging. MIBI coupled with either SIMS or 
TOF MS enables identification of up to 50 specific biolog-
ical protein markers at a greater resolution of 200 nm. A 
number of applications have demonstrated the capabili-
ties of MIBI applied to FFPE and fresh frozen tissues,81,82 
with possibilities for quantification.83 A superior benefit 
of MIBI is the application of the ion beam which allows 
for resampling after acquisition, in contrast to IMC which 
fully ablates the tissue. However, both techniques still 
have challenges with validating multiplexed images, for 
instance visual inspection of antibody specificity by 
expert pathologists which is crucial but increases the 
time of data analysis.
LA-ICP-MSI
An emerging technique in the world of biological MSI is 
LA-ICP-MSI. Despite being predominantly used previ-
ously to visualise the distribution of metallic elements 
in pathologies associated with metal-dependent 
Figure 5. IMC images demonstrating high spatial resolution capabilities by the detection of protein markers in 
normal mouse small intestine and colon tissues. Image obtained from Reference 75 Chang et al. 2017.
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processes,84 LA-ICP-MSI has been gaining momentum 
in other biomedical applications such as drug monitoring 
and receptor expression.85 One of the limitations of 
LA-ICP-MSI is the long time between sampling points in 
which the ablated aerosol is washed out of the ablation 
cell by the inert gases (e.g. He) to the ICP for ionisation 
(washout time). This increases analysis times and limits 
the practicality of the technique for clinical use. One 
solution would be increasing the sampling rate, but this 
causes ablated particles to mix and, therefore, decreases 
sensitivity.
Douglas et al.85 have designed a dual volume laser abla-
tion cell with an integrated ICP torch which leads to an 
increase in absolute sensitivity up to 14 times. A similar 
design has been employed by Van Acker et al.2 to achieve 
high resolution (sub µm), single cell imaging of membra-
nous receptors in breast cancer cell lines by attaching 
a specifically designed diethylenetriaminepentaacetic 
acid (DTPA) single-lanthanide chelate. The cells were 
concomitantly stained with a fluorophore which allows 
multi-imaging of the same sample without further sample 
preparation or sample denaturation. The group showed 
the potential of LA-ICP-MSI to offer more information on 
the microscopic binding pattern of membranous recep-
tors within single breast cancer cells when compared to 
established techniques such as confocal microscopy.85
Trapped ion mobility TOF instruments
The concept of separating isobaric species in MS has 
been extensively documented since the first ion mobility 
QTOF configured instrument became commercially avail-
able in 2006.86 The notion of trapping ions against a 
counter flow stream of gas then pushing ions through 
using the axial voltage of the trap, lead onto the newly 
developed instrumentation described by Fernandez-
Lima et al.87 Trapped ion mobility mass spectrometry 
(TIMS) provides an additional dimension of separation 
to complement high-performance QTOF technology 
that results in ion mobility resolution greater than 200. 
Similar to ion mobility capability, a buffer gas accelerates 
molecules in proportion to their collisional cross-section. 
The advantage of TIMS technology is the addition of an 
electric field that captures these separated ions based 
on their charge and thus narrow packets of ions can 
be released by altering the electric field, significantly 
increasing spectral resolution. If there are still unresolved 
peaks in the spectra, a narrow m/z window can be magni-
fied by adjusting the ion mobility resolution in the TIMS 
tunnel. This new technology is extremely powerful at 
resolving overlapping peaks for molecules with iden-
tical molecular masses. Spraggins et al.88 demonstrated 
high-resolution imaging capabilities of TIMS coupled 
to a TOF instrument to separate isobaric phosphatidyl-
choline species with 3 mDa mass difference in a whole-
body mouse pup section at 10 µm spatial resolution. The 
difference between these two species showed distinctive 
localisations; PC(34:3)H+ found throughout the tissue, 
absent within the brain and spinal cord, as PC(32:0)Na+ 
was significantly localised in the brain, spine and intes-
tines (Figure 6). The ability to separate these isobaric 
peaks, and thus identifying the differences in localisation, 
has potential to isolate results that significantly impact a 
study’s outcome.
Improving ionisation efficiency with MALDI-2
MALDI-2 was originally developed by Niehaus et al.,89 
from the University of Munster to increase sensitivity, 
mass accuracy and to achieve improvements in spatial 
resolution. Whilst the increase in spatial resolution is 
regarded generally as a benefit resulting in more detailed 
molecular imaging, sub-1 µm pixel size limits sensitivity 
by reducing the number of available ionised molecules 
compared to a larger ablation area. Considering that in 
MSI there is often a small amount of analyte available and 
that ionisation efficiencies for MALDI are in the region of 
1 × 10–4 and lower, detecting small quantities can present 
a problem.
This issue has been addressed with further advance-
ments in MS hardware with the development of the 
MALDI-2 instrumentation,90,91 where an orthogonal post-
ionisation laser triggers a secondary ionisation process of 
neutral molecules in the gas phase (Figure 7). This is 
reported to increase ion yields by up to two orders of 
magnitude. Recent applications include pharmaceutical 
research91 and cell biology,89 and report much-improved 
visualisation of compounds in comparison to conven-
tional MALDI approaches.
Data processing
Alongside the continuous pressure for technological 
advancement in MSI is the demand for user friendly, 
yet dynamic data processing and interpretation tools. 
The data generated in imaging experiments results in 
large complex data files (commonly >10 GB per image) 
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which require a multitude of post-image processing 
steps. Studying a biological molecule of interest within a 
tissue sample poses a range of potential challenges; post 
imaging software, therefore, needs to possess a range of 
toolbox functionalities to correct the issues arising from 
the sample preparation and image acquisition stages of 
the experiment described previously. These may include: 
normalisation, matrix signal removal, baseline correction, 
noise reduction, spectral alignment and spectral binning.
Each MSI instrument vendor proposes their own 
proprietary software for the processing of acquired image 
data. Many of these produce different file types, needing 
specific and expensive software to open. Although now a 
familiar concept amongst leading MSI communities, the 
development of the imzML file format was a pioneering 
initiative which aimed to address this issue.92 The aim 
of the imzML file format is to facilitate the sharing of 
imaging data despite the diverse instrumentation and 
data software currently being used within research groups. 
Schramm et al.92 reported on the potential positive impact 
that imzML could have on collaborative studies. A stan-
dardised file type that could enable comparison of images 
generated by diverse MSI instrumentation would allow 
efficient exchange of imaging files between institutions 
of academia, industries, health services and police forces. 
This file format for MSI is now employed in many free and 
commercially available software tools (Table 1).
Multifunctional options offering normalisation, image 
spectral analysis and advanced integration of multivariate 
statistics are now common in MSI. However, to enhance, 
improve and build on image processing strategies there 
is a need to streamline multidisciplinary modes of data 
capture along with the ability to be responsive to instru-
mental inconsistencies. Moreover, processing tools which 
consider sample batch variation and perform tissue 
comparisons not only across biological replicates but 
within the specimens themselves are necessary. Veselkov 
et al.100 described one such innovation and reported a 
processing platform named pyBASIS (Bioinformatics for 
MSI in Augmented Systems pathology). This system aims 
to seamlessly integrate large scale MSI data, molecular 
network analytics and histological data. pyBASIS features 
Figure 6. Whole-body mouse pup imaged with timsTOF at 10 µm. Ion mobility separation of 
two PC isobaric species localised in two different regions of the mouse pup. A) PC(34:3)H+ 
localised throughout the body. B) PC(32:0)NA+ significantly localised within the brain, spinal 
cord and intestines (adapted from Reference 88.)
Figure 7. Graphic demonstrating the differences in 
ionisation between MALDI and MALDI-2 and the cor-
responding tissue images gained by employing these 
ionisation methods. (Barre et al. 2019, Reference 91).
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Software tools that 
implement imzML file format Information brief
BioMap
Requires IDL Virtual Machine to run and no license required. Markus Stoekli: 
https://ms-imaging.org/wp/biomap/
MSiReader
Open source vendor-neutral MATLAB (Math Works) application. North 
Carolina State University: https://msireader.wordpress.ncsu.edu/
Cardinal
Statistical analysis package. Purdue and Northeastern University: https://cardi-
nalmsi.org/
DataCubeExplorer
Dynamic scrolling, spectral analysis and ROI function. FOM-AMOLF, 
Amsterdam: https://amolf.nl/download/datacubeexplorer
omniSpect
MATLAB-based tool for image visualisation and analysis: https://omictools.
com/omnispect-tool
SpectralAnalysis
Analysis software for spectral imaging data. University of Birmingham/NPL: 
https://research.birmingham.ac.uk/portal/en/datasets/spectralanalysis-soft-
ware-for-the-masses/
CycloBranch
Software tool for dereplication of organic compounds from MSI datasets: 
https://ms.biomed.cas.cz/cyclobranch/docs/html/
massPix
massPix is run using the R scripting interface; high quality images, multivari-
ate statistical analysis. MRC Human Nutrition Research and University of 
Cambridge, UK: https://omictools.com/masspix-tool
msiQuant
Quantification image visualisation including multiple interpolation methods. 
University of Uppsala: https://ms-imaging.org/wp/paquan/
SpectViewer
Manipulation of very large imaging data files without the requirement for bin-
ning. Jean-Pierre Both: https://ms-imaging.org/wp/imzml/software-tools/cea-
spect-viewer/
MSI.R
Open source software. CINVESTAV Unidad Irapuato, Mexico: http://lababi.
bioprocess.org/index.php/lababi-software/82-msi-r
MSIdV
MSI tool, MSIdV is implemented in Python 2.7 and is freely available. Kyushu 
University: https://sourceforge.net/projects/msidv/
LabMSI
Imaging software for MS. Katsutoshi Takahashi, AIST, Japan: http://www.bio-
image.org/~sltaka/LabMSI/
*SCiLS Lab
Unlimited size processing capacity and statistical analysis. By SCiLS, Bruker. 
Capable of 2-D and 3-D modes: https://scils.de/
*Quantinetix
Quantinetix imaging software normalises data for quantification. Imabiotech: 
https://www.imabiotech.com/quantinetix-mass-spec-imabiotech/
*MALDIVision
Bioinformatics tool for MALDI imaging, 2-D and 3-D modes. PREMIER Biosoft: 
http://www.premierbiosoft.com/maldi-tissue-imaging/index.html
*High Definition Imaging 
(HDI) Software
MSI software, fully integrated for multimodal experimental outputs. Waters: 
https://www.waters.com/waters/en_US/High-Definition-Imaging-(HDI)-
Software/nav.htm?cid=134833914&locale=en_US
 
TizViz 
Indigo Platform 
MSImage Viewer
Software tools currently under development 
TizViz has a beta version available (Christian Fuchsberger), Indigo Platform also 
includes DESI image processing (Prosolia, RanyJullian) and MSImage Viewer is 
employed in imaging analysis within Novartis (Stoekli lab).
Table 1. A summary of software tools currently used and under development in MSI that support the imzML file format 
(* commercial tools).93–99
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pattern recognition approaches and employs intuitive 
“instrumental learning” which focusses on inter-sample 
(between samples) as opposed to intra-sample (within 
a sample) normalisation. The differences in normalisa-
tion between inter and intra is either a scaling factor 
applied equally for all spectra within a specific sample or 
normalisation via the total ion count, respectively, i.e. per 
spectrum normalisation. The pyBASIS multi-integrated 
software aims to play a major role in the amalgamation 
between research and clinically relevant data.
“MassImager”, a software tool produced by He et al.,101 
focuses on in-depth MSI analytics yet employs a user 
friendly approach at the in situ metabolomics level. 
This processing platform claims to allow “artificial intel-
ligent pathological diagnosis” and is particularly useful for 
metabolomic toxicity data. The reasoning behind this is 
the high-throughput data processing function facilitating 
observation of pharmacokinetics—absorption, distribu-
tion, metabolism and excretion.
Visualisation of endogenous biological molecules can 
be linked to the presence of other species that co-exist 
within a tissue specimen. Elemental analysis is one 
example of how the distribution of biomarkers can be 
linked to the pathological basis of disease or a specific 
disease state. “LA-iMageS” is a sophisticated tool devel-
oped to study both qualitative and quantitative elemental 
spatial distribution.102 The user is able to visualise an 
element of interest in a two- or three-dimensional rota-
tional colour map. This open source tool is reported to be 
easy to operate, omitting the necessity of prior bioinfor-
matics expertise.
The ability to observe both isolated and co-localised 
signals offers many advantages that would be extremely 
relevant for pathological and toxicity studies.
Conclusion/future perspective
The published research within the dynamic field of MS 
reports innovations in efficient ionisation, mass selection 
and detection, along with multifunctional data processing 
analytics. Despite cutting edge techniques there will 
always be a common ground amongst the MS community, 
i.e. an expectation from users of continual advancement 
in all areas that remains constant. Robust reproducible 
analytical data is vital, without compromising instru-
mental sensitivity and mass accuracy; an incessant chal-
lenge in itself. Whether these remarkable instruments 
are used individually or as a combined system, here now 
remains an exciting future for MSI, whatever the area of 
research may be.
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